Sanders Bill Would Allow Biosimilar “Pay-For-Data” System

Biosimilar manufacturers could buy access to existing clinical trial data to use in their applications and avoid conducting some clinical trials, if a bill filed by Sen. Bernard Sanders, I-Vt., is approved.